What's in MediWound Ltd's pipeline?

MediWound Ltd has 6 drugs in our index: 3 marketed, 0 filed, 2 in Phase 3, 1 in Phase 2, 0 in Phase 1.

Which companies overlap with MediWound Ltd's portfolio?

Top competitors by shared drug class: Healthpoint.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/mediwound-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-15 · How we verify

MediWound Ltd — Portfolio Competitive Intelligence Brief

MediWound Ltd pipeline: 3 marketed, 0 filed, 2 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 2 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Nexobrid	anacaulase	marketed			Dermatology	2022-01-01
NexoBrid	NexoBrid	marketed	Enzymatic debriding agent	Bromelain (serine protease)	Wound Care / Burn Treatment
NEXOBRID	ANACAULASE-BCDB	marketed			Other
DGD	DGD	phase 3	Enzymatic debridement agent	Denatured collagen and extracellular matrix proteins	Wound Care / Burn Treatment
EscharEx (EX-03)	EscharEx (EX-03)	phase 3	Enzymatic debriding agent	Proteolytic enzymes (bromelain-derived)	Wound Care / Burn Treatment

Therapeutic area mix

Wound Care / Burn Treatment · 3
Dermatology · 1
Other · 1
Wound care · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Healthpoint · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for MediWound Ltd:

Cite this brief

Drug Landscape (2026). MediWound Ltd — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/mediwound-ltd. Accessed 2026-05-15.